ing do not fully meet these criteria, 21 and therefore novel TSPs are required for transcriptional targeting of gliomas.
The recently discovered survivin gene encodes the survivin protein, a member of the IAP protein family, which plays an important role in the survival of cancer cells and the progression of malignancy. Members of the IAP family directly inhibit terminal effector caspases through baculovirus IAP repeat-dependent recognition, thereby preventing apoptosis. 4, 24 Survivin is normally expressed during embryogenesis and is undetectable in fully differentiated adult tissues. 6 In contrast, survivin is repeatedly expressed in a broad spectrum of human cancers including brain, breast, pancreas, esophageal, and ovarian tumors.
Survivin-mediated suppression of apoptosis and growth factor-independent cell survival is implicated in the resistance of the tumor to standard therapy. In this regard, 80% of GBM cells demonstrate abundant survivin expression, 6 and a clear correlation is seen between the histological grade of a glioma and the fraction of survivin-positive tumor samples. In glioma tumors, survivin expression is also correlated with a resistance to chemo-and radiotherapy and with poor prognosis. 6, 15, 34 Given this promising role for survivin, we developed a survivin promoter-based adenoviral vector for the purpose of transcriptional targeting of gliomas. We hypothesized that this strategy of tumor-specific regulation of gene expression could provide a novel transcriptional targeting approach for human gliomas. Furthermore, we used this survivin TSP approach in the context of CRAds use for tumor-selective viral replication and oncolysis. To achieve this goal, a TSP is required to control E1 gene expression in the adenovirus. Although other TSPs have been previously suggested in the context of glioma, such as hTERT, 19, 20 oncostatin-M promoter (a hematopoietic cytokine), the vascular endothelial growth factor promoter, 30 the c-Myc promoter activated in medulloblastoma, 37 and gas1, 44 in this study we identified the survivin promoter as a uniquely transcriptional targeting strategy for human glioma.
Materials and Methods

Cells, Tissues, and Animals
Samples of the human glioma tumor cell lines U251MG, U87MG, U373MG, D54MG, and D65MG were kind gifts from Dr. G. Y. Gillespie (Department of Neurosurgery, University of Alabama at Birmingham). Samples of the M59K and U118MG cell lines were obtained from the American Type Culture Collection (Manassas, VA). Cells of the U87MG line were cultured in minimal essential medium (Mediatech, Herndon, VA) containing 15% FBS (HyClone, Logan, UT), 2 mM L-glutamine, penicillin (100 IU/ml), and streptomycin (100 g/ml). The other cell lines-U251MG, D54MG, U118MG, M59K, and D65MG-were cultured in DMEM-Ham F12 50:50 (Mediatech) containing 10% FBS and supplemented with L-glutamine, penicillin, and streptomycin as previously described. In addition, 911 cells (a kind gift from Dr. Van Der Eb, Leiden University, The Netherlands) were maintained in DMEM. Each medium was also supplemented with fetal calf serum, penicillin, and streptomycin. Astrocyte cells, a kind gift from Dr. Charles Bonus, were cultured in DMEM and supplemented with 10% FBS, penicillin, and streptomycin. Three primary glioma tumor cells, VU84, VU119, and VU78, 23 were cultured in DMEM with 10 to 15% FBS, L-glutamine, and antibiotic agents. The cells were incubated at 37˚C in a 95% air/5% CO 2 environment under humidified conditions.
Human liver samples were separated from donor hepatectomy remnants that had been obtained during liver transplantation; the study was approved by the local internal review board. To generate human liver organ cultures, the tissue was serially dissected into 0.5-mm-thick slices by using a Krumdieck tissue slicer (Alabama Research Development, Munford, AL). Next, the liver tissue was cultured in 24-well plates in RPMI medium supplemented with 10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, and 5 g/ml insulin. The tissue cultures were maintained at 37˚C in a humidified atmosphere of 95% air/5% CO 2 . Three tissue slices were examined per group. Female C57BL/6 mice and female BALB/c nude mice (6-8 weeks of age; Charles River, Wilmington, MA) were used in the in vivo experiments. All animals received humane care based on guidelines established by the American Veterinary Association. All experimental protocols involving live animals were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham.
Adenoviral Vectors
The following recombinant adenoviral vectors and CRAds were constructed in our lab. The recombinant adenoviral vectors reAdGL3BCox2 (or Ad-Cox2), 42 reAdGL3Midkine (or Ad-Mk), 1 reAdGL3BSurvivin (or Ad-S), 45 and reAdGL3BCMV (or Ad-CMV), each of which was used in this experiment, are all isogenic in that they are composed of the pGL3B plasmid adenoviral backbone, which carries the same luciferase cassette but under the control of different promoters, that is, Cox-2, midkine, survivin, or CMV, respectively. Two CRAds-CRAd-S-S and CRAd-S-Lwere generated by our group and have been described elsewhere. 47 In these CRAds, the adenoviral native E1 promoter was completely deleted and the AD5 E1 gene was regulated by a short survivin promoter, S-S (nucleotides Ϫ230 to ϩ30), or a longer segment, S-L (nucleotides Ϫ1430 to ϩ30). To increase the killing of glioma cancer cells, these CRAd genomes also contain a capsid modification, RGD-4C, which was inserted genetically into the viral capsid. As a replicative control for the survivin-CRAds, we used a wild-type adenovirus (Adwt). The viral particle/plate forming unit ratio for each virus was 34 for CRAd-S-S and 16 for CRAd-S-L.
Analysis of Survivin Promoter Activity in Glioma Cells
A recombinant adenoviral vector, AdSurvivin, was used in this study as reported previously. 45 To determine the transcriptional activity of the survivin promoter, 5 ϫ 10 4 cells of each established glioma cancer cell line (U87MG, M59K, U251MG, U118MG, D65MG, and D54MG), primary glioma cells, and normal controls (primary mesothelial cells, derived in our department from ascites fluid, and keratinocytes), were plated into 24-well tissue plates and infected with Ad-CMV, Ad-Cox2, Ad-Mk, or Ad-S at an MOI of 100 (100 vp/cell) in 200 l of growth medium containing 2% FBS (infection medium). The infection medium was replaced by fresh medium containing 10% FBS after 2 hours. Twenty-four hours postinfection, luciferase activity was determined using the Reporter Lysis Buffer and Luciferase Assay System (Promega, Madison, WI) following the manufacturer's protocol. Experiments were performed in triplicate, and luciferase activities are presented as relative light units normalized to the CMV promoter activity.
Quantitative Real-Time PCR for Detection of the Human Survivin Gene and Ad5 E4 Gene Expression
Total cellular RNA or DNA was extracted from cell cultures in 6-well plates by using the RNeasy mini RNA extraction kit or the blood DNA kit (Qiagen, Valencia, CA). Both RNA and DNA samples were treated with RNase-free DNase and DNase-free RNase, respectively, to remove possible contamination. The survivin gene transcripts were detected in RNA samples by using an oligo pair (forward primer 5ЈTGGAAGGCTGGGAGCCA and reverse primer 5ЈGAAAGCGCAACCGGACG) and the probe (ORF6TGACGA CCCCATAGAGGAACATAAAAAGCAT); the Ad5 E4 gene was detected in DNA samples by using an oligo pair (forward primer 5ЈGGAGTGCGCCGAGACAAC and reverse primer 5ЈACTACG TCCGGCGTTCCAT) and the probe (ORF6TGGCATGACAC TACGACCAACACGATCT). The oligos were designed using Primer Express (version 1.0; Perkin-Elmer, Foster City, CA) and synthesized by Applied Biosystems. Specifics of the real-time PCR reaction have been described by us elsewhere. 45, 46 Negative controls without templates were included in each reaction series, and an internal control (human GAPDH or ␤-actin) was used to normalize the copy number for the survivin and E4 genes.
Survivin Promoter Activity in Normal Human Brain Tissue
Specimens of normal human brain were obtained following approval from our internal review board and consisted of 200-m slices of gray matter from the temporal lobe, which were acquired during surgery for epilepsy. The brain slices were prepared as previously described by Verwer, et al. 40 Experiments were performed on normal brain slices excised from two patients with epilepsy. On Day 2, the brain specimens were infected in quadruplicate with 2 ϫ 10 8 vp of Ad-S or Ad-CMV. On Day 5, the brain specimens were harvested and the luciferase assays were performed.
Analysis of CRAd Replication in Tumor Cell Lines
Glioma cells (10 5 /well) were cultured in the manner described earlier, infected with 100 vp/cell of CRAd-S-S, CRAd-S-L, Adwt, or Ad-S in infection medium containing 2% FBS, and incubated at 37˚C in a 95% air/5% CO 2 environment. After 2 hours in incubation, the infection medium was removed, the cells were washed three times with PBS, and the cells were placed in fresh culture medium with 10% FBS. Media from triplicate wells were collected 1, 3, and 9 days postinfection; DNA was extracted from 200 l of media by using the DNeasy Tissue Kit (Qiagen), and quantitative real-time PCR was performed in the manner described earlier. The adenovirus E4 gene copy numbers were detected.
Replication of CRAd in the Human Liver
Human liver organ cultures, described earlier, were infected with CRAd-S-S, CRAd-S-L, Adwt, or Ad-S (10 8 vp/slice, ~ 500 vp/cell) and incubated at 37˚C in a humidified atmosphere of 95% air/5% CO 2 . Three tissue slices were included per group. After a 2-day incubation, total DNA was extracted from the human liver organ cultures by using the DNeasy Tissue Kit (Qiagen). The DNA samples were treated with DNase-free RNase to remove possible RNA contamination and were stored at Ϫ80˚C until use. The Ad5 E4 gene copy numbers were detected and normalized by referral to human GAPDH.
Analysis of In Vitro Glioma Cell Killing
The in vitro cytocidal effects of CRAd-S-S and CRAd-S-L were analyzed by performing crystal violet staining. Briefly, 25,000 cells (including D65MG, U251MG, U373MG, U87MG, U118MG, or OV4, an ovarian cancer cell line used as a control) per well were plated onto a 24-well plate, and the cells were infected at 100, 10, 1, and 0 vp/cell with CRAd-S-S, CRAd-S-L, or Ad-S in infection medium. Two hours later, the infection medium was replaced with complete medium. After 10 more days of culture, the cells were fixed with 10% buffered formalin for 10 minutes and stained with 1% crystal violet in 70% ethanol for 20 minutes, followed by washing three times with tap water and air drying. Trypan blue exclusion experiments also were performed.
Analysis of CRAd Replication in Glioma Xenografts
The U118MG glioma cells were injected into the flanks of nude mice (5 ϫ 10 6 cells in 200 l PBS per tumor, five animals/group). When the resulting tumors reached 5 mm in diameter, 5 ϫ 10 8 vp of CRAd-S-S or Adwt diluted in 50 l PBS were injected into each tumor. On Days 1 and 7 postinjection, the tumors were collected and snap-frozen with dry ice/ethanol. The DNA was extracted, and the relative E4 copy numbers were determined.
Antitumor Effect of CRAd on Mouse Xenografts
Five BALB/c nude mice in each group were inoculated in the flanks with 5 ϫ 10 6 U118MG cells. The tumor cells were verified to have 95% viability by Trypan blue exclusion. When the tumor reached 5 mm in its widest diameter, 10 9 vp of viral vector (CRAd-S-S, CRAd-S-L, or Ad-S) or PBS was injected intratumorally. The vector Ad-S was used as a nonreplicative control virus with an identical viral backbone. The same dose was repeated after 1 week. Tumor volumes were monitored twice a week, and the volumes were calculated by using the formula 1/2 xy 2 , where x is the longest diameter and y the shortest diameter of the tumor. Based on the determined volume, the following equations were applied.
Tumor volume ratio = tumor volume at Day 30/tumor volume at Day 1 ϫ 100%.
Tumor growth inhibition rate = 100% Ϫ (tumor volume at Day 30/ tumor volume at Day 1 ϫ 100%).
Statistical Analysis
The luciferase activities measured in this study were analyzed by performing the Student t-test using commercial software (Statistics Analysis Software version 8.2; SAS Inc., Cary, NC). A probability value less than 0.05 was considered statistically significant.
Results
Survivin Promoter is Active in Both Established and Primary Glioma Cells
Four recombinant adenoviral vectors, Ad-Cox2, Ad-Mk, Ad-S, and Ad-CMV, were used in these experiments. All recombinant adenoviruses are isogenic, thereby allowing the determination of promoter activity via reporter gene expression. The CMV promoter in Ad-CMV is constitutively active, thereby serving as a positive control to allow normalization for each given cell line. The data shown in Fig. 1 represent promoter activity in established and primary low-passage glioma cells. Of all three TSPs, the survivin promoter exhibited the highest activity in the established glioma cell lines, with a mean of 11.2% of the activity of the CMV promoter. In contrast, both the Cox-2 and midkine promoters were relatively inactive, showing less than 4% of the activity of the CMV promoter. The differences were significant (p Ͻ 0.01). All three promoters were inactive in both normal primary mesothelial cells and the normal keratinocyte cell line. Because established cancer cell lines may not reflect the true nature of cancer cells, we repeated these experiments in primary low-passage glioma cells. Again, we observed that the survivin promoter was the most active of all three promoters in three primary glioma cells. The mean survivin promoter activity was 20% of the activity of the CMV promoter in three primary cells, but with wide variation among the three cell types (5, 12.5, and 42.5% of the activity of the CMV promoter in VU84, VU119, and VU78 cells, respectively). The mean Cox-2 and midkine promoter activities were less than 5% of the CMV promoter. Thus, the survivin promoter is repressed in normal cells and is active in both established and primary glioma cells.
Survivin Promoter is Less Active in Normal Astrocytes and Normal Human Brain
A critical determinant of any candidate transcriptional targeting approach for glioma is tumor specificity. In the previous section, we described our study of survivin promoter activity in glioma cells. Next, we tested whether this promoter may be applicable to glioma gene therapy, that is, whether it is inactive in the normal brain. To this end, we evaluated survivin promoter activity in normal astrocytes and normal brain tissue. First, D65MG glioma cells and astrocytes were infected with either Ad-S or Ad-CMV (Fig.  2 upper right) . The survivin promoter activity in the D65MG glioma cell line (12.6% of the activity of the CMV promoter) was 12-fold higher than that in astrocytes (1% of the activity of the CMV promoter). This pattern correlates well with survivin gene expression (Fig. 2 upper left) . The transcript levels of the survivin gene were sixfold higher in the D65MG glioma cell line (310 copies/ng RNA) than in primary astrocytes (48 copies/ng RNA). Thus, high levels of survivin gene expression and survivin promoter activity were observed in glioma cells but not in normal astrocytes.
To examine the tumor selectivity of the survivin promot- er more fully, normal human cerebral cortex tissues, which were excised during epilepsy surgeries performed in two patients, were evaluated for survivin promoter activity (Fig.  2 lower) . Normal human cerebral cortex displayed less activity, showing only 0.26% of the activity of the CMV promoter (p Ͻ 0.01). Thus, the survivin promoter is downregulated in the normal human brain.
Survivin-CRAds Induce Cytotoxicity in Glioma Cell Lines
Encouraged by the glioma-specific activity of the survivin promoter, we used two CRAds that had been constructed by this group and described previously 47 as oncolytic antiglioma agents. The short segment of the survivin promoter, CRAd-S-S, and the long segment of the survivin promoter, CRAd-S-L, were evaluated to determine their cell-killing effect in a variety of glioma cell lines. Cytotoxicity was evaluated after 10 days of incubation by staining the tissue with crystal violet (Fig. 3) . Although the replication-incompetent Ad-S vector had no cytotoxic effect even at 100 vp/cell, the survivin-based CRAds induced cytotoxicity in all glioma cancer cell lines. Oncolytic efficiency, however, varied in the glioma cell lines tested. While survivin-based CRAds were highly efficient even at 1 vp/cell in D65MG cells, cytotoxicity was observed at 10 vp/cell for CRAd-S-S and 100 vp/cell for CRAd-S-L in U251MG, U87MG, and U118MG cells; and cytotoxicity was observed for both CRAds only at 100 vp/cell in U373MG cells. In contrast, the OV4 ovarian cancer cells were resistant to the survivin-based CRAds. Thus, both
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FIG. 2. Expression of the survivin gene in glioma cells. Upper Left:
Basal survivin gene expression is increased in glioma D65MG cells and is decreased in astrocytes. The results were obtained by performing quantitative real-time PCR for survivin transcripts. Total RNA was extracted from 10 6 cells. Real-time PCR reactions for transcripts of the human survivin gene or the control housekeeping gene GAPDH or ␤-actin were performed under conditions described in Materials and Methods. The survivin transcriptional levels in both the D65MG cells and astrocytes were normalized to GAPDH levels and expressed as survivin copies per nanogram of RNA. *p Ͻ 0.05 and **p Ͻ 0.01 for a comparison of survivin transcripts in normal astrocytes and D65MG glioma cells. Upper Right: Specific survivin promoter activity correlates with basal survivin gene expression. Glioma D65MG cells and normal astrocytes were infected with Ad-S or Ad-CMV, respectively, at an MOI of 100. Luciferase activity was analyzed after 2 days of infection and is presented as percentages of CMV promoter activity. The values represent mean values of triplicate assays, and each point represents the mean and SD from three determinations. *p Ͻ 0.05 and **p Ͻ 0.01 for a comparison of survivin promoter activities in normal astrocytes and D65MG glioma cells. Lower: Survivin promoter activity is decreased in normal human brain. Survivin promoter activity was measured in human brain specimens excised from two patients during epilepsy surgeries. Normal brain specimens were infected in quadruplicate with either Ad-S or Ad-CMV. After a 72-hour incubation, luciferase activity was measured. Each point represents the mean and the SD from four determinations. **p Ͻ 0.01 for a comparison of survivin and CMV promoter activities.
CRAd-S-S and CRAd-S-L show substantial oncolytic activity in established glioma cell lines.
Survivin Promoter-Regulated CRAds are Inactive in the Human Liver
Due to the fact that adenoviral replication is species specific and because the major adenoviral toxicity in gene therapy trials is hepatic, we tested the replication of survivinCRAds in human liver specimens in organ cultures. To evaluate viral replication indirectly, we measured E4 gene copy numbers with quantitative real-time PCR, performed on DNA isolated from human liver slices 2 days after infection with CRAd-S-S, CRAd-S-L, or Adwt (Fig. 4) . The E4 copy numbers of the CRAd-S-S and CRAd-S-L agents were 1.5 and 2.5 orders of magnitude fewer than that of Adwt, respectively. Thus, survivin promoter-regulated CRAds exhibit a "liver-off" profile, especially CRAd-S-L.
Replication of Survivin-CRAds In Vitro and In Vivo
Next, CRAd-S-S and CRAd-S-L replications were compared in vitro to Adwt replication in D65MG glioma cells. Viral replication was determined indirectly by examining the E4 gene copy numbers on Days 1, 3, and 9 postinfection (Fig. 5 upper) . The E4 copy numbers of CRAd-S-S (3.2 million copies on Day 3 and 12.8 million copies on Day 9) were higher than both CRAd-S-L (1.1 million copies on Day 3 and 2.3 million copies on Day 9) and Adwt (0.34 and 2.86 million copies on Days 3 and 9, respectively). On a time scale, the replication rates increased twofold, fourfold, and 8.3-fold from Day 3 to Day 9 for CRAd-S-L, CRAd-S-S, and Adwt, respectively. Thus, despite their decreased replication in the human liver, CRAd-S-L and CRAd-S-S maintain their replicative potential in glioma cells.
Because no established glioma xenograft animal models involve the use of D65MG cells, we used U118MG glioma cells. Xenografts of U118MG cells were injected with either Adwt or CRAd-S-S, and harvested either on Day 1 or Day 7 after injection. Next, DNA was extracted from tumor samples and the E4 gene copy numbers were measured using quantitative real-time PCR (Fig. 5 lower) . The E4 copy numbers increased to 815 copies/ng DNA in tumors injected with Adwt and 2574 copies/ng DNA in tumors injected with CRAd-S-S; these increases constitute a 50-fold and a 160-fold increase in the replication rate on Day 7 for cells ) from each cell line-D65MG, U251MG, U373MG, U87MG, U118MG, and OV4-were placed in 24-well plates and infected with adenoviral vector at the indicated MOIs or were mock infected. After a 10-day infection period, the cells were stained with crystal violet as described in Materials and Methods.
FIG. 4.
Bar graph demonstrating that the replication of survivinbased CRAds is repressed in human liver organ cultures. The replication of survivin-based CRAds was evaluated in human liver slices, which had been infected with 500 vp/cell of an adenovirus (Adwt, Ad-S, CRAd-S-S, or CRAd-S-L). Two days following infection, DNA was isolated from each human liver slice and the Ad5 E4 levels were determined by performing quantitative PCR. The data are expressed as the adenoviral E4 copy number per nanogram DNA following normalization to GAPDH. treated with Adwt and CRAd-S-S, respectively. Thus, although both Adwt and CRAd replicate well in vivo in a glioma xenograft model, survivin promoter-regulated CRAd replication was superior to that of Adwt.
Antitumor Effects of Survivin-CRAds
The antitumor effects of CRAd-S-S and CRAd-S-L were analyzed in vivo in the U118MG xenograft model (Fig. 6) . A follow-up examination of tumor volume showed that both survivin-based CRAds could significantly inhibit tumor growth. As Fig. 6 upper demonstrates, tumor volumes were 37.5 Ϯ 6.7 mm , and 167.6 Ϯ 49 mm 3 30 days after the animals were injected with CRAd-S-S, CRAd-S-L, Ad-S, and PBS, respectively. When tumor volumes were compared with those on Day 1 (Fig. 6 lower) , a 62.1% volume reduction rate was observed for tumors treated with CRAd-S-S and a 67.2% volume reduction rate for tumors treated with CRAd-S-L after 30 days. In contrast, relative tumor volumes increased to 160% in the non-replicative virus-treated group and 225% in the PBS-treated group. There is a statistically significant difference (p Ͻ 0.01) between treatment groups and control groups. Thus, although the antitumor effects did not differ between the two survivin-based CRAds, both CRAds exhibited a strong antitumor effect in the U118MG glioma xenograft model.
Discussion
Malignant gliomas (GBM and anaplastic astrocytoma) are the most common types of primary central nervous system tumors and together have an incidence of 5 to 8 per 100,000 persons. The median survival of patients with malignant glioma varies from 14 weeks among those who receive conservative treatment to 40 to 59 weeks for those who receive aggressive therapy. 8, 14, 32, 33 Because survival in patients with malignant glioma remains poor, novel strategies are urgently required. In this regard, oncolytic virotherapy with CRAd agents is a promising and emerging approach that is already used in other types of cancer. 16, 28 The hallmark of oncolytic virotherapy is the potential for tumor-
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Transcriptional targeting of glioma using the survivin promoter ) were placed in 24-well plates and infected with CRAd-S-S, CRAd-S-L, Adwt, or a nonreplicating adenovirus, Ad-S, at an MOI of 100. Two hundred microliters of medium was removed from each well on Days 1, 3, and 9. The DNA was isolated using a Qiagen column, and the amount of E4 gene was determined using quantitative PCR as described in Materials and Methods. The E4 gene levels are shown as copy numbers on the y axis. All experiments in each group were performed in triplicate. Lower: Replication of CRAd-survivin-RGD in vivo. Tumor cells (5 ϫ 10 6 ) were injeced in both flanks. Ten days later, 5 ϫ 10specific replication and cell killing. To this end, transcriptional targeting is essential. In our previous reports we identified the survivin promoter as an excellent TSP that exhibits a "tumor-on" and "liver-off" profile. 45 In this study, we focused on the survivin promoter as a key regulatory TSP for glioma. First, we demonstrated, in a recombinant adenoviral vector background, that the survivin promoter is active in a variety of established and primary glioma cells. This promoter activity correlated well with the native survivin gene expression pattern in these glioma cells. Encouraged by these findings, we used survivin promoter-regulated CRAds, in which the E1 gene was driven by the human survivin promoter, to achieve tumor-specific oncolysis. Although these survivin-CRAds demonstrated a glioma cell-killing capacity in vitro as well as in vivo, we detected only minimal viral transcription in normal human cells including astrocytes. Consequently, survivin-based promoter transcriptional regulation emerges as a potentially applicable antitumor approach for glioma.
Other promoters have been proposed for glioma-specific therapy, such as glial fibrillary acidic protein (a brain-specific expression but not a TSP) and the hTERT TSP. 19, 20 In this study, the Cox-2 and midkine promoters were compared with the survivin promoter on the basis of their proven potential for glioma. 2, 18, 27 Although all three TSPs were repressed in normal cells, the survivin promoter demonstrated superior activity in both established glioma cell lines (with a mean 11.2% of the activity of the CMV promoter compared with a mean of Ͻ 4% activity of the CMV promoter for the Cox-2 and midkine promoters; Fig.  1 upper) . More importantly, the activity in primary glioma cells was 20% of the activity of the CMV promoter compared with a mean of less than 5% activity of the CMV promoter for the Cox-2 and midkine promoters (Fig. 1 lower) .
Although decreased expression of survivin gene in normal tissues is expected, 5 it is encouraging that the promoter is expressed in glioma cells, especially in view of the correlation between survivin expression levels and the prognosis ) were injected subcutaneously into both flanks of nude mice. When the tumor reached 5 mm in diameter, administration of adenoviral vectors (10 9 vp) including a nonreplicative adenovirus, Ad-S, or PBS was performed by intratumoral injection. A second administration of adenoviral vectors or PBS was given 1 week later. The tumor volume was calculated using the formula 1/2 xy of glioma. 6 Moreover, the increasing expression of survivin in progressive grades of astrocytic tumors has important clinical application, as survivin-based therapies can be implemented across a spectrum of malignant brain tumors. 15 Given that replication-incompetent vectors have proved to be inefficient as antitumor agents, replication-selective viruses have emerged as potentially powerful anticancer agents. 17 Based on their capacity for gene amplification and intratumoral production of viral progeny, the intrinsic cell killing of adenoviruses has been diverted into CRAd oncolysis. These attributes of CRAds have recently been applied in the context of glioma. 25, 36 In this study, we constructed two novel CRAd agents, CRAd-S-S (nucleotides Ϫ230 to ϩ30 of the human survivin gene) and CRAd-S-L (nucleotides Ϫ1430 to ϩ30 of the human survivin gene), in which the survivin promoter regulated Ad5 E1 gene expression and viral infectivity was enhanced by capsid modification, that is, genetic insertion of the RGD-4C ligand. Of note, the E3 gene was retained in these CRAds for improved cell killing. Nevertheless, despite the cell killing attributes of our survivin-based CRAds, they maintained safe profiles in both normal brain and liver. Because the liver manifests a 95% uptake rate of adenovirus when delivered systemically, 22 thereby potentially compromising liver function, 39 the safety profile of survivin-based CRAds in liver tissue (1.5 and 2.5 orders of magnitude fewer E4 copies than those found in Adwt, CRAd-S-S, and CRAd-S-L, respectively) is especially encouraging. Furthermore, because malignant gliomas do not metastasize, local CRAd injection may be applicable on the basis of dramatic repression of the survivin promoter in normal human astrocytes and brain tissue.
The in vitro oncolytic effects of CRAd-S-S and CRAd-S-L were translated into antitumor effects in a glioma xenograft model and correlated with intratumoral replication rates. The difference we observed between the short and long versions of the survivin promoter in the CRAd context was that the long version of the survivin promoter was less hepatotoxic than the short version. These data are reminiscent of the Cox-2 promoter versions previously described. 41, 43 Thus, CRAd-S-L maintains an antitumor effect, while minimizing hepatotoxicity to increase the therapeutic index, an important parameter in cancer gene therapy.
In this study, the viral replication of CRAds was regulated by a tumor-specific promoter, the survivin promoter. Thus, viral replication was limited to tumor cells and minimized in normal host cells. However, adenoviruses are able to kill normal cells as well as cancer cells by leaking vectors, leading to host toxicity. 11 The potential of killing normal cells relates to the promoter activity in normal cells. For this reason, we tested the promoter activity in human brain tissue. The data shown in Fig. 2 lower revealed only 0.26% of the activity of the CMV promoter, indicating that the toxicity of leakage of these agents to brain tissue is low because of the TSP.
Conclusions
We identified the human survivin promoter as a tumorspecific regulatory element for glioma. It is activated in established and primary glioma cells and is downregulated in normal astrocytes and human brain and liver tissues. The survivin promoter therefore represents a promising transcriptional targeting approach for gliomas. Survivin-based CRAds significantly kill glioma cells in vitro and inhibit the growth of glioma xenografts in vivo. On this basis, the survivin promoter in recombinant adenovirus and CRAd contexts may have potential use for future experimental clinical applications in the treatment of glioma.
